SEQUENTIAL HIGH-DOSE METHOTREXATE AND FLUOROURACIL COMBINED WITH DOXORUBICIN - A STEP AHEAD IN THE TREATMENT OF ADVANCED GASTRIC-CANCER - A TRIAL OF THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER GASTROINTESTINAL-TRACT COOPERATIVE GROUP

被引：340
|
作者：
WILS, JA
KLEIN, HO
WAGENER, DJT
BLEIBERG, H
REIS, H
KORSTEN, F
CONROY, T
FICKERS, M
LEYVRAZ, S
BUYSE, M
DUEZ, N
机构：
[1] DE WEVER HOSP,HEERLEN,NETHERLANDS
[2] UNIV COLOGNE,MED KLIN,W-5000 COLOGNE 41,GERMANY
[3] INST JULES BORDET,B-1000 BRUSSELS,BELGIUM
[4] CTR ALEXIS VAUTRIN,F-54500 VANDOEUVRE NANCY,FRANCE
[5] CHU VAUDOIS,CH-1011 LAUSANNE,SWITZERLAND
[6] RADBOUD HOSP,NIJMEGEN,NETHERLANDS
[7] MARIA HILF KRANKENHAUS,MONCHEN GLADBACH,GERMANY
[8] EUROPEAN ORG RES TREATMENT CANC,CTR DATA,BRUSSELS,BELGIUM
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1991年 / 9卷 / 05期
关键词：
D O I：
10.1200/JCO.1991.9.5.827
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate (MIX), fluorouracil (5-FU), and Adriamycin (doxorubicin; Farmitalia Carlo Erba, Milan, Italy) (FAMTX) or 5-FU, Adriamycin, and mitomycin (FAM). The results show a significantly superior response rate (41% v 9% [P < .0001]), and survival (median, 42 weeks v 29 weeks [P = .004]) for FAMTX. There was a cumulative thrombocytopenia in FAM and not in FAMTX. The FAMTX protocol should be the reference treatment in future clinical trials that seek to improve the therapeutic outcome in advanced gastric cancer. © 1991 by American Society of Clinical Oncology.
引用
收藏
页码：827 / 831
页数：5
相关论文
共 50 条
  • [21] Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer:: European organization of research and treatment of cancer gastrointestinal group study 40952
    Köhne, CH
    Wils, J
    Lorenz, M
    Schöffski, P
    Voigtmann, R
    Bokemeyer, C
    Lutz, M
    Kleeberg, U
    Ridwelski, K
    Souchon, R
    Ei-Serafi, M
    Weiss, U
    Burkhard, O
    Rückle, H
    Lichinitser, M
    Langenbuch, T
    Scheithauer, W
    Baron, B
    Couvreur, ML
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3721 - 3728
  • [22] Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms
    Frederic Lehmann
    Denis Lacombe
    Patrick Therasse
    Alexander MM Eggermont
    Journal of Translational Medicine, 1 (1)
  • [23] DOXORUBICIN AND 5-FLUOROURACIL VERSUS DOXORUBICIN AND ORAL FTORAFUR IN THE TREATMENT OF ADVANCED GASTRIC-CANCER - A PHASE-II AND PHASE-III TRIAL
    VESTLEV, PM
    PEDERSEN, H
    ACTA ONCOLOGICA, 1990, 29 (07) : 945 - 946
  • [24] THROMBOEMBOLIC COMPLICATIONS AFTER PERIOPERATIVE CHEMOTHERAPY IN WOMEN WITH EARLY BREAST-CANCER - A EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER BREAST-CANCER COOPERATIVE GROUP-STUDY
    CLAHSEN, PC
    VANDEVELDE, CJH
    JULIEN, JP
    FLOIRAS, JL
    MIGNOLET, FY
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) : 1266 - 1271
  • [25] DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
    CHEVALLIER, B
    FUMOLEAU, P
    KERBRAT, P
    DIERAS, V
    ROCHE, H
    KRAKOWSKI, I
    AZLI, N
    BAYSSAS, M
    LENTZ, MA
    VANGLABBEKE, M
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) : 314 - 322
  • [26] European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer
    De Ruysscher, Dirk
    Faivre-Finn, Corinne
    Moeller, Ditte
    Nestle, Ursula
    Hurkmans, Coen W.
    Le Pechoux, Cecile
    Belderbos, Jose
    Guckenberger, Matthias
    Senan, Suresh
    RADIOTHERAPY AND ONCOLOGY, 2017, 124 (01) : 1 - 10
  • [27] PROGNOSTIC FACTORS IN SUPERFICIAL BLADDER-TUMORS - A STUDY OF THE EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER - GENITOURINARY TRACT CANCER COOPERATIVE GROUP
    DALESIO, O
    SCHULMAN, CC
    SYLVESTER, R
    DEPAUW, M
    ROBINSON, M
    DENIS, L
    SMITH, P
    VIGGIANO, G
    SOLOWAY, MS
    JOURNAL OF UROLOGY, 1983, 129 (04): : 730 - 733
  • [28] FLUOROURACIL, DOXORUBICIN, AND MITOMYCIN COMBINATION VERSUS PELF CHEMOTHERAPY IN ADVANCED GASTRIC-CANCER - A PROSPECTIVE RANDOMIZED TRIAL OF THE ITALIAN-ONCOLOGY-GROUP-FOR-CLINICAL-RESEARCH
    COCCONI, G
    BELLA, M
    ZIRONI, S
    ALGERI, R
    DICOSTANZO, F
    DELISI, V
    LUPPI, G
    MAZZOCCHI, B
    RODINO, C
    SOLDANI, M
    GILLI, G
    FINARDI, C
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) : 2687 - 2693
  • [29] PHASE-II TRIAL WITH 5-FU, HIGH-DOSE METHOTREXATE, EPIRUBICIN AND CISPLATIN (FEMTX-P) IN ADVANCED GASTRIC-CANCER
    CONROY, T
    WILS, J
    PAILLOT, B
    WAGENER, DJT
    BURGHOUTS, JTM
    FICKERS, MMF
    DEGRAEFF, A
    LALISANG, FM
    BULLETIN DU CANCER, 1993, 80 (03) : 255 - 260
  • [30] Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer
    Klaassen, U
    Wilke, H
    Seeber, S
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 32 - 37
12345